ArticleMolecular neurobiology2025
Longitudinal Analysis of Estrogen Receptor Gene Methylation, Estradiol, and Depressive Symptoms During the Perinatal Period.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
DNA methylation of estrogen receptor genes (ESR1, ESR2, and GPER) may affect the expression of the estrogen receptors (ERs) alpha, beta, and G protein-coupled estrogen receptor (GPER). Altered receptor expression may in turn affect the receptors' sensitivity to estrogen, thereby modulating vulnerability to depression during periods of estrogen fluctuation. The aim of this study was to investigate the association between the methylation of ESR1, ESR2, and GPER, depressive symptoms, and estradiol during the perinatal period using a longitudinal design. A total of 159 women were followed longitudinally from 34 to 36 weeks of gestation to 8-12 weeks postpartum. Depressive symptoms were assessed using the Edinburgh Postnatal Depression Scale (EPDS). Salivary estradiol levels were quantified, and DNA methylation was analyzed using dried blood spots. Multivariate linear regressions and paired t-tests were used for analysis. Depressive symptoms were negatively associated with the mean overall ESR1 methylation during pregnancy (β = -0.41, p = 0.002), but not during the postpartum period (p ≥ 0.05). Haplotype CA during pregnancy (p ≤ 0.001) and haplotype TA (p = 0.03) during postpartum modified the relationship between depressive symptoms and overall mean ESR1 DNAm. No associations emerged for ESR2, GPER, or estradiol at either time point (all p ≥ 0.05). The mean overall methylation of ESR1 increased from pregnancy to postpartum (t = -2.59, p = 0.012) and was positively associated with depressive symptom scores during pregnancy (β = 0.418, p = 0.031). This work suggests that lower DNA methylation levels of ESR1, which may reflect higher ER-alpha expression and thus greater sensitivity to estrogen, are associated with increased depressive symptoms during pregnancy. The findings highlight molecular pathways of estrogen sensitivity, particularly via ER-alpha, as a promising target for future biomarker research for perinatal depression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.